Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
Abstract Hematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought to evaluate the dynamics of immune response to BNT162b2 mRNA vaccine in HSCT recipients. We systematically proposed vaccination with BNT162b2...
Main Authors: | Mathieu Leclerc, Rabah Redjoul, Anne Le Bouter, Florence Beckerich, Christine Robin, Vincent Parinet, Cécile Pautas, Dehbia Menouche, Selwa Bouledroua, Lydia Roy, Ludovic Cabanne, Yakout Nait-Sidenas, Slim Fourati, Sébastien Maury |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-03-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-022-01250-2 |
Similar Items
-
Breakthrough Covid‐19 infections in vaccinated recipients of allogeneic stem cell transplantation
by: Slim Fourati, et al.
Published: (2022-08-01) -
Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients
by: Christine Robin, et al.
Published: (2017-12-01) -
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
by: Jonathan Bordat, et al.
Published: (2023-02-01) -
Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
by: Abdelhakim Ahmed-Belkacem, et al.
Published: (2022-08-01) -
A comparison of the effect of xinruibai versus filgrastim on hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation
by: Qixiang Ye, et al.
Published: (2018-05-01)